Autor(es)

Carvalho, Maria Fernanda Lopes ; de Almeida, Bruna Oliveira ; Bueno, Maura Lima Pereira ; Vicari, Hugo Passos ; Lima, Keli ; Roversi, Fernanda Marconi ; Machado-Neto, Joao Agostinho

• Tipo de documento: Artigo Científico
• Fonte: Hematology, Transfusion and Cell Therapy; v. 46, n. 3, p. 10-pg., 2024-06-08.

Resumo

Myeloid neoplasms result from molecular alterations in hematopoietic stem cells, with acute myeloid leukemia (AML) being one of the most aggressive and with a poor prognosis. Hematopoietic cell kinase (HCK) is a proto-oncogene that encodes a protein-tyrosine kinase of the Scr family, and it is highly expressed in AML. The present study investigated HCK expression in normal hematopoietic cells across myeloid differentiation stages and myeloid neoplasm patients. Within the AML cohort, we explored the impact of HCK expression on clinical outcomes and its correlation with clinical, genetic, and laboratory characteristics. Furthermore, we evaluated the association between HCK expression and the response to antineoplastic agents using ex vivo assay data from AML patients. HCK expression is higher in differentiated subpopulations of myeloid cells. High HCK expression was observed in patients with chronic myelomonocytic leukemia, chronic myeloid leukemia, and AML. In patients with AML, high levels of HCK negatively impacted overall and disease-free survival. High HCK expression was also associated with worse molecular risk groups and white blood cell count; however, it was not an independent prognostic factor. In functional genomic analyses, high HCK expression was associated with several biological and molecular processes relevant to leukemogenesis. HCK expression was also associated with sensitivity and resistance to several drugs currently used in the clinic. In conclusion, our analysis confirmed the differential expression of HCK in myeloid neoplasms and its potential association with unfavorable molecular risks in AML. We also (AU)

• Processo FAPESP: 20/12842-0 - Impacto da ancestralidade genética no desenvolvimento, características moleculares e desfecho clínico em pacientes adultos com Leucemia Linfoblástica Aguda
• Beneficiário: Keli Cristina de Lima
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 19/23864-7 - Análise compreensiva de dados genômicos para identificação e validação de novos alvos terapêuticos envolvidos na regulação de citoesqueleto celular em Leucemias agudas
• Beneficiário: João Agostinho Machado Neto
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 22/11038-8 - Investigação de vias de sinalização e processos biológicos associados à proteína ANKHD1 em Câncer de Estômago
• Beneficiário: Bruna Oliveira de Almeida
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 22/14505-6 - Investigação do potencial antineoplásico da inibição farmacológica de ezrina em tumores sólidos: adenocarcinoma gástrico e carcinoma cervical
• Beneficiário: Maria Fernanda Lopes Carvalho
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 21/11606-3 - Investigação dos efeitos antineoplásicos de novos inibidores de PIP4K2 e HDAC em neoplasias hematológicas
• Beneficiário: João Agostinho Machado Neto
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 21/01460-1 - Investigação do potencial antineoplásico de novos fármacos que modulam a dinâmica de microtúbulos em Leucemia Mieloide Aguda
• Beneficiário: Hugo Passos Vicari
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto